ea0029oc9.6 | Endocrine Tumours & Translation | ICEECE2012
Mohamed A.
, Blanchard M.
, Albertelli M.
, Niccoli P.
, Monges G.
, Garcia S.
, Moutardier V.
, Delpero J.
, Enjalbert A.
, Florio T.
, Ferone D.
, Saveanu A.
, Barlier A.
Somatostatin analogs (SSAs) such as octreotide (OCT) are currently effective in controlling most hypersecretion associated symptoms of Gastoenteropancreatic-neuroendocrinetumors (GEP-NETs). The results of the phase IIIb PROMID trial showed that OCT doubled time to progression for patients with metastatic neuroendocrine midgut tumors compared with placebo. SSAs act on different intracellular pathways through different somatostatin receptor (Sst) subtypes. While OCT is mainly an...